Hexacath, independant European company - Bio Active Coronary Stents

Our company

Dedicated to AMI

HEXACATH is an independent European company founded in 1994 in France which develops, manufactures and distributes innovative devices in interventional cardiology dedicated to treat patients affected with Myocardial Infarction (MI) such as the unique Bio Active Coronary Stent (BAS) TiTAN OPTIMAX dedicated to AMI with coronary lesions and the one and only Microcirculation catheter RAYFLOW dedicated to AMI with non obstructive coronary arteries.

HEXACATH is a fully integrated company from R&D to distribution.

Innovations in the field of medical technology to treat myocardial infarction with or without coronary lesions is the force driving Hexacath. In-house R&D combined with cutting edge equipment and high tech machines in Hexacath clean rooms allow faster development from the original idea to the final product.

According to the WHO, cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.

Myocardial infarction (MI) usually known as “heart attack” is mainly caused by a blockage preventing blood from flowing to the heart and in this case the most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that supply the heart.

Targeting MI, Hexacath has developed a unique Bioactive coating based on a material known as Titanium-Nitride-Oxide for its Bio Active Stent (BAS) TiTAN OPTIMAX.

This patented technology has proven its ability to reduce thrombosis occurrence versus DES as well as restenosis levels versus BMS through a reduction of inflammatory reactions and platelet aggregation while capable of promoting healing post stenting thus reducing the need for prolonged Anti Platelet Treament (Dual or Single).

Coronary Microvascular Dysfunction (CMD) known as ANOCA (Angina with non obstructive Coronary Arteries) or MINOCA (Myocardial Infarction with Non Obstructive Coronary Arteries) may affect up to 50% of patients with ischemia visiting cath-labs that do not present with significant epicardial stenosis.

It took nearly 10 years to Hexacath to develop and patent the RayFlow microcatheter, an innovative technology, which is about to become the Key to understand and treat coronary microcirculation dysfunction.

Our MISSION, is to serve the community of interventional cardiologists to diagnose and treat patients suffering from myocardial infarction in order to save their lives. To accomplish this goal the Hexacath mission is based on medical device innovations and close partnerships with Key Opinion Leaders cardiologists.